Coherus is collobarating with BAX to commercialize an Enbrel FoB in the EU, Canada, and Brazil (#msg-91645674) and is collaborating with Daiichi Sankyo in Japan, South Korea, and Taiwan (#msg-75397629). The US market is not being pursued because of AMGN’s long-running patent protection (#msg-69263618).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”